Search

Bio-Techne Corp

Затворен

СекторЗдравеопазване

72.4 0.28

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

72.03

Максимум

72.25

Ключови измерители

By Trading Economics

Приходи

13M

51M

Продажби

16M

311M

P/E

Средно за сектора

103.029

57.002

EPS

0.51

Дивидентна доходност

0.44

Марж на печалбата

16.392

Служители

3,100

EBITDA

21M

99M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

-1.86% downside

Дивиденти

By Acuity

Дивидентна доходност

Средно за сектора

0.44%

2.22%

Следващи печалби

4.11.2026 г.

Следваща дата на дивидент

28.08.2026 г.

Следваща дата на екс-дивидент

24.08.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

2.7B

11B

Предишно отваряне

72.12

Предишно затваряне

72.4

Настроения в новините

By Acuity

59%

41%

291 / 340 Класиране в Healthcare

Bio-Techne Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.08.2026 г., 19:16 ч. UTC

Correlated Moves
News

Bio-Techne Corp corrected its dividend record date to August 24, 2026. Shares are trading roughly flat amid broader market dynamics.

5.08.2026 г., 19:16 ч. UTC

Correlated Moves

Bio-Techne Corp's shares are lower today, reflecting declines in the Russell 2000 Index. The stock remains near the upper end of its one-month trading range.

4.08.2026 г., 22:02 ч. UTC

Correlated Moves

Bio-Techne Corp shares are higher in after-market trading, buoyed by positive sentiment from U.S.-Iran negotiations and gains in major technology stocks.

3.08.2026 г., 19:26 ч. UTC

Correlated Moves

Bio-Techne Corp is advancing, reflecting broader market positivity amid gains in major tech stocks and falling energy prices. The stock is near its one-month trading range high.

31.07.2026 г., 22:02 ч. UTC

Correlated Moves

Bio-Techne Corp shares are lower in after-market trading amid a broader market downturn, reflecting negative sentiment impacting price action.

30.07.2026 г., 18:26 ч. UTC

Correlated Moves

Bio-Techne Corp is trading roughly flat as the broader market recovers from declines, influenced by rising Treasury yields and inflation concerns.

29.07.2026 г., 22:03 ч. UTC

Bio-Techne Corp shares are lower in after-market hours, reflecting a decline since Wednesday's close amid cautious market sentiment and geopolitical tensions.

20.07.2026 г., 18:01 ч. UTC

Bio-Techne Corp shares are lower today, with no specific news identified. Broader market pressures include rising yields and inflation concerns linked to oil prices.

Сравнение с други в отрасъла

Ценова промяна

Bio-Techne Corp Прогноза

Ценова цел

By TipRanks

-1.86% надолу

12-месечна прогноза

Среден 70.89 USD  -1.86%

Висок 73 USD

Нисък 62 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Bio-Techne Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

11 ratings

1

Купи

10

Задържане

0

Продай

Настроение

By Acuity

291 / 340 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat